Diligence memo · auto-generated · as of July 3, 2026

Walk-in Dermatology Management, Inc.

Walk-in Dermatology Management, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Walk-in Dermatology Management, Inc. operates in Other Health Care, based in Roslyn.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Walk-in Dermatology Management, Inc. has raised $4.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.0M on 2021-12-22.

Most recent recorded round closed around 2021-12-22.

Valuation (modeled)modeled

Provath models Walk-in Dermatology Management, Inc. at approximately $39M (range $2.5M–$208M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.10× the median modeled value of Seed Other Health Care companies in 2019–2021 (211 peers) — value vs value, same stage and era. Within the normal band (110% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 40 months.

Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 3.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 61% of Other Health Care peers (5377 compared).

Modeled value ranks above 63% of those peers.

Closest niche peers: Crossroads at Delta Memory, Noninvasix, Inc., CPIV Haven Holdings, LLC, Cane Ip Key Holdings, Llc, Hospi Corp.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.